BRIEF published on 09/18/2024 at 07:05, 1 year 11 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 11 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 11 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 11 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 11 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 11 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 years ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 2 years ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 years 1 month ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 2 years 1 month ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 08/25/2026 at 23:05, 1 hour 10 minutes ago Faraday Copper Shareholders Approve Share Issuance in Connection with the Acquisition of the San Manuel Project
Published on 08/25/2026 at 15:00, 9 hours 15 minutes ago Four Nines Gold Intersects Hydrothermal Breccia in First Three Holes at Hayden Hill
Published on 08/25/2026 at 14:30, 9 hours 45 minutes ago First Breach Completes First Flight of Drone Prototype and Advances American-Made Manufacturing Through Hellbender Agreement
Published on 08/25/2026 at 14:30, 9 hours 45 minutes ago Tintina Mines Completes Strategic Partnership Transaction, Consolidating 100% Ownership of the Dos Amigos (formerly Domeyko Sulfuros) Copper-Gold Project in Chile
Published on 08/25/2026 at 22:35, 1 hour 39 minutes ago ZOOPUNK Makes Its Opening Night Live Debut at gamescom 2026
Published on 08/25/2026 at 20:35, 3 hours 39 minutes ago Michter's Named the #1 Most Admired Whiskey in the World by Drinks International in New 2026 Ranking
Published on 08/25/2026 at 18:57, 5 hours 17 minutes ago EQS-Adhoc: net digital AG significantly exceeds expectations for revenue and EBITDA in the first half of 2026
Published on 08/25/2026 at 17:45, 6 hours 29 minutes ago EQS-Adhoc: MPC Oceanic Group raises forecast for the financial year 2026
Published on 08/25/2026 at 17:45, 6 hours 30 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 6 hours 30 minutes ago Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026
Published on 08/25/2026 at 08:30, 15 hours 45 minutes ago Eiffage wins several contracts worth a total of €132 million in the healthcare sector
Published on 08/24/2026 at 18:00, 1 day 6 hours ago Outstanding shares and voting rights statement at 31 July 2026
Published on 08/24/2026 at 17:59, 1 day 6 hours ago Saint-Gobain strengthens its positioning in construction chemicals and light construction in Latin America
